Join us for the third and final webinar in our 2020 series on decisions in the United States and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 3 of this series will focus on recent key developments in the United States and Europe, including:

• Recent decisions and developments in the United States which may impact biologics and biosimilars, including Arthrex v Smith & Nephew, AAM v Becerra, and GSK v Teva.
• Recent decisions and developments in Europe, including the Santen CJEU decision, enforcement of personalized medicine claims, and the UK’s guidelines for biosimilars post Brexit.